Immupharma PLC PROF. SYLVIANE MULLER AWARDED 'LEGION D'HONNEUR'
30 Septiembre 2021 - 1:14AM
RNS Non-Regulatory
TIDMIMM
Immupharma PLC
30 September 2021
REACH| 30 SEPTEMBER 2021
ImmuPharma PLC
("ImmuPharma", the "Company" or the "Group")
PROF. SYLVIANE MULLER AWARDED PRESTIGIOUS
'LEGION D'HONNEUR'
ImmuPharma PLC (LSE:IMM; Euronext Growth Brussels: ALIMM), the
specialist drug discovery and development company, is delighted to
announce that Prof. Sylviane Muller, inventor of Lupuzor(TM) and
P140 technology and a key collaboration partner, has been awarded
the highly prestigious Legion d'honneur Award.
The ' Remise des insignes d'officier de la Légion d'honneur' was
presented to Prof. Muller at an
awards ceremony yesterday evening at l'Institut de Science et
d'Ingénierie Supramoléculaires (ISIS) in Strasbourg.
The 'Legion of Honor' is the highest French decoration and one
of the most famous in the world. For two centuries, being
established in 1802 by Napoleon Bonaparte, it has been retained by
all later French governments and presented on behalf of the Head of
State to reward the most deserving citizens in all fields of
activity.
Commenting on this award, Tim McCarthy, CEO and Chairman of
ImmuPharma, said:
" On behalf of the Board and the whole team at ImmuPharma, we
congratulate Prof. Muller on this highly prestigious award, which
is highly deserving, in recognition of her many years of work and
commitment to understanding the complexities of the human immune
system. We are hugely honoured to be working in partnership with
Prof. Muller on Lupuzor(TM) and the P140 platform, in which her
passion and drive and collaborative approach has been an invaluable
contribution to our clinical team, as we move closer to offering
therapeutic drugs, initially in lupus, which will be of enormous
benefit to patients."
End
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chief Executive Officer &
Chairman + 44 (0) 207 152 4080
Lisa Baderoon, Head of Investor Relations
& Non-Executive Director + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 36 8 3550
Stanford Capital Partners (Joint Broker)
Patrick Claridge +44 20 3650 3650
John Howes
Bob Pountney
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Gunther De Backer +32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, metabolic diseases,
anti-infectives and cancer. The lead program, Lupuzor(TM), is a
first-in class autophagy immunomodulator which is in Phase 3 for
the treatment of lupus and preclinical analysis suggest therapeutic
activity for many other autoimmune diseases that share the same
autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals
signed on 28 November 2019, an exclusive licence and development
agreement and trademark agreement for Lupuzor(TM) to fund a new
international Phase 3 trial for Lupuzor(TM) and commercialise in
the US.
For additional information about ImmuPharma please visit
www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code:
213800VZKGHXC7VUS895.
About Legion d'honneur
The Legion of Honor is the highest French decoration and one of
the most famous in the world. For two centuries, being established
in 1802 by Napoleon Bonaparte, it has been retained by all later
French governments and presented on behalf of the Head of State to
reward the most deserving citizens in all fields of activity.
The order's motto is Honneur et Patrie ("Honour and
Fatherland"), and its seat is the Palais de la Légion d'Honneur
next to the Musée d'Orsay , on the left bank of the Seine in Paris
.
The order is divided into five degrees of increasing
distinction: Chevalier ( Knight ), Officier (Officer), Commandeur (
Commander ), Grand officier (Grand Officer), and Grand-croix (
Grand Cross ). For more information go to:
www.legiondhonneur.fr/en
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASDUSMSEFSESU
(END) Dow Jones Newswires
September 30, 2021 02:14 ET (06:14 GMT)
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024